Nilotinib significantly induces apoptosis in imatinib resistant K562 cells with wild-type BCR–ABL, as effectively as in parental sensitive counterparts

References

• Baran Y, Salas A, Senkal CE et al. Alterations of ceramide/ sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 2007; 282: 10922–10934.
   PubMed Web of Science ®Google Scholar
• Koca E, Haznedaroglu IC. Imatinib mesylate and the managementof chronic myeloid leukemia (CML). Turk J Hematol 2005; 2(4): 161–172.
   Google Scholar
• Deininger MW, Goldman JM, Melo TV. The molecular biology ofchronic myeloid leukemia. Blood 2000; 96: 3343–3356.
   PubMed Web of Science ®Google Scholar
• Peled A, Hardan I, Trakhtenbrot L et al. Immature leukemic CD34±CXCR4± cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1. Stem Cells 2002; 20: 259–266.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, le Coutre P, Mologni L et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL± leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997; 23: 380–394.
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472–480.
   PubMed Web of Science ®Google Scholar
• Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000; 289: 1938–1942.
   PubMed Web of Science ®Google Scholar
• Baran Y, Ural AU, Gunduz U. Mechanisms of cellular resistanceto imatinib in human chronic myeloid leukemia cells. Hematology 2007; 12: 497–503.
   PubMed Web of Science ®Google Scholar
• Frame D. New strategies in controlling drug resistance. J ManagCare Pharm 2007; 13: 513–S17.
   Google Scholar
• Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880.
   PubMed Web of Science ®Google Scholar
• Illmer T, Schaich M, Platzbecker U et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18: 401–408.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006; 94: 1765–1769.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542–2551.
   PubMed Web of Science ®Google Scholar
• Nagar B, Bornmann WG, Pellicena P et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62: 4236–4243.
   PubMed Web of Science ®Google Scholar
• O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Cioffi CL, Law N et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139–145.
   PubMed Web of Science ®Google Scholar
• Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by ST1571. Blood 2001; 97: 2440–2448.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Talpaz M, O'Brien S et al. High-rates of major cytogenetic response in patients with newly diagnosed chronic myeloid leukemia in early chronic phase treated with imatinib at 400 mg or 800 mg daily. Blood 2002; 100: 95a.
   Web of Science ®Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652.
   PubMed Web of Science ®Google Scholar
• Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–3539.
   PubMed Web of Science ®Google Scholar
• Bartolovic K, Balabanov S, Hartmann U et al. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 2004; 103: 523–529.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Breitenstein W et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129–141.
   PubMed Web of Science ®Google Scholar
• DeRemer DL, Ustun C, Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther 2008; 30: 1956–1975.
   PubMed Web of Science ®Google Scholar
• Kerkela R, Grazette L, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908–916.
   PubMed Web of Science ®Google Scholar
• le Coutre P, Ottmann OG, Giles F et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant acceler-ated-phase chronic myelogenous leukemia. Blood 2008; 111: 1834–1839.
   PubMed Web of Science ®Google Scholar
• Plosker GL, Robinson DM. Nilotinib. Drugs 2008; 68: 449–459.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Walters DK, Deininger MW, Druker BJ. AMN107: tightening the grip of imatinib. Cancer Cell 2005; 7: 117–119.
   PubMed Web of Science ®Google Scholar
• Cortes J, Deininger M. Chronic myeloid leukemia. New York: Informa Healthcare, 2006.
   Google Scholar